Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369756 · ClinicalTrials.gov registry record · NA
Prontosan Quality of Life Study in Patients With Chronic Leg Wound(s)
A NA study, sponsored by B. Braun Medical.
- Terminated
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT03369756: Clinical Trial NA study, sponsored by B. Braun Medical.
NCT03369756 is a NA study that was terminated before completion, run by B. Braun Medical. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03369756, a NA study, was terminated before completion, sponsored by B. Braun Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study evaluates the use of Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel in the treatment of chronic leg wounds in adults. All participants will use Prontosan and report their personal observations regarding Quality of Life.
Primary Outcome
The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess "Body", "Psyche" and "Everyday Life". These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice. Each individual item is rat
Interventions
- DEVICE Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2019-09-25 |
| Phase | NA |
Why NCT03369756 stopped before completion
NCT03369756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Prontosan Wound Irrigation Solution and Prontosan Wound Gel is the first listed.
NCT03369756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03369756 about?
NCT03369756 is a clinical study titled "Prontosan Quality of Life Study in Patients With Chronic Leg Wound(s)". This study evaluates the use of Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel in the treatment of chronic leg wounds in adults. All participants will use Prontosan and report their personal observations regarding Quality of Life.
What is the current status of trial NCT03369756?
This trial is currently terminated. It is a NA study. The enrollment target is 43 participants. The study started on 2018-02-20. Estimated completion is 2019-09-25.
What interventions are being tested in trial NCT03369756?
The interventions under investigation include: Prontosan Wound Irrigation Solution and Prontosan Wound Gel (DEVICE).
Who is sponsoring clinical trial NCT03369756?
This trial is sponsored by B. Braun Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03369756's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI